Objetivo
Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of multidrug resistant (MDR) Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa. There is an unmet medical need to prevent P. aeruginosa infection in critically ill patients and to develop new antibiotics for infections caused by Gram-negative bacteria (GNB). The Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections (COMBACTE-MAGNET) consortium will provide groundbreaking multinational phase 2 and phase 3 studies in adult intensive care unit (ICU) patients and a phase 1 paediatric safety and PK study with the bispecific immunoglobulin (IgG)1 mAb (MEDI3902) targeting the pathogenic components PsI and PcrV as a new approach for preventing P. aeruginosa infections, especially pulmonary infections, in ICU patients. In addition, the consortium will perform phase 1 and phase 2 studies, including extensive pharmacokinetic/pharmacodynamic (PK/PD) studies, with a new beta‐lactam ‐ AIC499 ‐ with enhanced beta‐lactamase stability and in vitro/ in vivo activities against MDR-GNB, including P. aeruginosa and Acinetobacter spp. Alone, or in combination with a beta‐lactamase inhibitor (BLI), AIC499 is active against MDR isolates producing a wide range of beta‐lactamases, and therefore, offers the real prospect of a new treatment option for patients with life-threatening infections due to MDR GNBs. The COMBACTE-MAGNET consortium brings together 5 pharmaceutical industry partners and 36 academic partners, and is a true nexus of world class researchers from 10 European countries with expertise in (i) designing and executing observational and interventional studies related to antibiotic‐resistant bacteria; (ii) conducting high‐quality research in the epidemiology, prevention, and treatment of infections caused by MDR‐GNB, (iii) identifying novel biomarkers in critically ill patients; (iv) performing Phase I PK/PD studies; (v) performing Phase 2 studies enriched for PK/PD endpoints; and (vi) performance of large definitive Phase 3 randomized controlled trial (RCT) for regulatory purposes. The two European Federation of Pharmaceutical Industries and Associations (EFPIA) project sponsors, MedImmune and AiCuris, will provide all required study‐related expertise in clinical development of monoclonal antibodies and antibiotics with MEDI3902 and AIC499 plus BLI as Investigational Medicinal Products (IMPs), respectively. Key strengths of the COMBACTE-MAGNET consortium is its direct links to the ND4BB Topic 1 COMBACTE network (Clinical Trial Network [CLIN‐Net], Laboratory Trial and Research Network [LAB-Net], and Statistical Trial and Research Network [STAT‐net]), the ND4BB Topic 5 COMBACTE-CARE consortium, participation of the Paediatric European Network for the Treatment of AIDS and Infectious Diseases (PENTA-ID) network for pediatric infection studies, and the European Forum for Good Clinical Practice (EFGCP), a not‐for‐profit, Innovative Medicines Initiative (IMI)‐ and FP7‐funded, organization specialized in delivering tailor‐made, practice‐relevant Good Clinical Practice (GCP) training activities in European Union (EU) countries. The clinical studies related to MEDI3902 and of AIC499 will be supported by innovative epidemiological studies, including mathematical modeling of the consequences of P. aeruginosa infections. Furthermore, detailed biomarker studies will be performed to explore associations of host biomarkers (e.g. pre‐existing antibodies against P. aeruginosa virulence factors, protein biomarkers, and ribonucleic acid (RNA) molecules) and infections, disease severity and outcome, which will enhance the successful execution of clinical trials. Finally, COMBACTE-MAGNET will set up an unprecedented collaboration, called EPI-Net, to map and organize available surveillance systems in Europe in order to optimize surveillance o
Ámbito científico
- medical and health scienceshealth sciencespublic healthepidemiologyepidemics prevention
- medical and health sciencesclinical medicinecritical care medicine
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Convocatoria de propuestas
IMI-JU-11-2013
Consulte otros proyectos de esta convocatoria
Régimen de financiación
JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)Coordinador
151 85 Sodertaelje
Suecia
Ver en el mapa
Participantes (39)
3584 CX Utrecht
Ver en el mapa
2000 Antwerpen
Ver en el mapa
1211 Geneve
Ver en el mapa
72074 Tuebingen
Ver en el mapa
6525 XZ Nijmegen
Ver en el mapa
41071 Sevilla
Ver en el mapa
79106 Freiburg
Ver en el mapa
OX1 2JD Oxford
Ver en el mapa
89081 Ulm
Ver en el mapa
8006 Zurich
Ver en el mapa
75013 Paris
Ver en el mapa
08036 Barcelona
Ver en el mapa
1011 Lausanne
Ver en el mapa
28046 MADRID
Ver en el mapa
WC1E 6BT London
Ver en el mapa
35127 Padova
Ver en el mapa
1050 Bruxelles / Brussel
Ver en el mapa
1105AZ Amsterdam
Ver en el mapa
07120 Palma
Ver en el mapa
87000 Limoges
Ver en el mapa
75654 Paris
Ver en el mapa
42117 Wuppertal
Ver en el mapa
BS10 5NB Bristol
Ver en el mapa
3015 GD Rotterdam
Ver en el mapa
L69 7ZX Liverpool
Ver en el mapa
RG6 1PT Reading
Ver en el mapa
La participación finalizó
BS8 1QU Bristol
Ver en el mapa
1180 Vienna
Ver en el mapa
08007 Barcelona
Ver en el mapa
1090 Wien
Ver en el mapa
TW89GS Brentford
Ver en el mapa
4058 BASEL
Ver en el mapa
94250 GENTILLY
Ver en el mapa
75012 Paris
Ver en el mapa
L7 8XP LIVERPOOL
Ver en el mapa
BS16 1QY Bristol
Ver en el mapa
1200 Bruxelles / Brussel
Ver en el mapa
69978 Tel Aviv
Ver en el mapa
37129 Verona
Ver en el mapa